Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma

被引:41
|
作者
Moratin, Julius [1 ]
Metzger, Karl [1 ]
Safaltin, Ayse [1 ]
Herpel, Esther [2 ,3 ]
Hoffmann, Juergen [1 ]
Freier, Kolja [1 ,4 ]
Hess, Jochen [5 ,6 ]
Horn, Dominik [1 ,4 ]
机构
[1] Heidelberg Univ Hosp, Dept Oral & Craniomaxillofacial Surg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany
[3] Natl Ctr Tumor Dis NCT, Tissue Bank, Heidelberg, Germany
[4] Saarland Univ Hosp, Dept Oral & Maxillofacial Surg, Homburg, Germany
[5] Heidelberg Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Heidelberg, Germany
[6] German Canc Res Ctr, Res Grp Mol Mech Head & Neck Tumors, Heidelberg, Germany
关键词
HNSCC; immune checkpoint; lymph node metastases; PD-L1; PD-L2; EXPRESSION; RECURRENT; PEMBROLIZUMAB; PATHWAY; RECOGNITION; PROGRESSION; DISSECTION; RESISTANCE; RELEVANCE; NIVOLUMAB;
D O I
10.1002/hed.25713
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background This study aimed on evaluating the expression levels of the immune checkpoint proteins, PD-L1 and PD-L2, in tissue specimens of 175 oral squamous cell carcinomas (OSCC) and 33 corresponding lymph node metastases (LNM). Methods Tissue microarrays of primary OSCC and matched LNM were investigated via immunohistochemistry regarding PD-L1/PD-L2 expression. Results were compared for primary tumors and corresponding metastases and correlated with clinicopathological data. Results PD-L1 expression in cancer cells correlated significantly with tumor size, and the presence of regional metastases (P < 0.01). PD-L1 expression was significantly higher in metastases as compared to primary OSCC (P < 0.05). Overall survival was significantly worse in patients with higher levels of PD-L1 and PD-L2 score (P < 0.05). Conclusions This is the first publication to compare PD-L1 and PD-L2 expression in primary OSCC and matched LNM. The results indicate that anti-PD-1 therapy may be of therapeutic use even in early stage OSCC to prevent further progression.
引用
收藏
页码:2484 / 2491
页数:8
相关论文
共 50 条
  • [31] Evaluating PD-L1 in Cytology to Determine Eligibility for Anti-PD-1/PD-L1 Immunotherapy in Patients with Head and Neck Squamous Cell Carcinoma
    Liu, Zhonghua
    Roy-Chowdhuri, Sinchita
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 246 - 247
  • [32] Comparison of PD-L1 assays in head and neck carcinoma
    Jeong, Ji-seon
    Jo, Uiree
    Choi, Gyuheon
    Song, Halim
    Cho, Kyung-ja
    PATHOLOGY, 2024, 56 (07) : 969 - 981
  • [33] Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma
    Hsieh, Chih-Cheng
    Hsu, Han-Shui
    Li, Anna Fen-Yau
    Chen, Yann-Jang
    JOURNAL OF THORACIC DISEASE, 2018, 10 (07) : 4433 - 4444
  • [34] PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report
    Nagasaka, Misako
    Zaki, Mark
    Kim, Harold
    Raza, S. Naweed
    Yoo, George
    Lin, Ho-sheng
    Sukari, Ammar
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [35] Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma
    Hirshoren, Nir
    Al-Kharouf, Issa
    Weinberger, Jeffrey M.
    Eliashar, Ron
    Popovtzer, Aron
    Knaanie, Ariela
    Fellig, Yakov
    Neuman, Tzahi
    Meir, Karen
    Maly, Alexander
    Vainer, Gilad W.
    ONCOLOGY, 2021, : 464 - 470
  • [36] A comparative study of PD-L1 diagnostic assays in squamous cell carcinoma of the head and neck (SCCHN)
    Ratcliffe, M. J.
    Sharpe, A.
    Rebelatto, M.
    Scott, M.
    Barker, C.
    Scorer, P.
    Walker, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma
    Puladi, Behrus
    Ooms, Mark
    Kintsler, Svetlana
    Houschyar, Khosrow Siamak
    Steib, Florian
    Modabber, Ali
    Hoelzle, Frank
    Knuechel-Clarke, Ruth
    Braunschweig, Till
    CANCERS, 2021, 13 (17)
  • [38] PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
    Evrard, D.
    Hourseau, M.
    Couvelard, A.
    Paradis, V.
    Gauthier, H.
    Raymond, E.
    Halimi, C.
    Barry, B.
    Faivre, S.
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [39] Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)
    de Ruiter, Emma J.
    Mulder, Frans J.
    Koomen, Bregje M.
    Speel, Ernst-Jan
    van den Hout, Mari F. C. M.
    de Roest, Reinout H.
    Bloemena, Elisabeth
    Devriese, Lot A.
    Willems, Stefan M.
    MODERN PATHOLOGY, 2021, 34 (06) : 1125 - 1132
  • [40] Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck
    De Meulenaere, Astrid
    Vermassen, Tijl
    Aspeslagh, Sandrine
    Huvenne, Wouter
    Van Dorpe, Jo
    Ferdinande, Liesbeth
    Rottey, Sylvie
    ORAL ONCOLOGY, 2017, 70 : 34 - 42